Lexicon Pharmaceuticals, Inc.

415 articles about Lexicon Pharmaceuticals, Inc.

• New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology

  3/4/2023

  Lexicon Pharmaceuticals, Inc., announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational product sotagliflozin presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana.

• Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update

  3/2/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and full-year ended December 31, 2022 and provided an update on key corporate milestones.

• Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023

  2/28/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2022 financial results on Thursday, March 2, 2023 after the markets close.

• New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology

  2/20/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana.

• Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference

  1/6/2023

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 41st Annual JP Morgan Healthcare Conference, taking place January 9-12, 2023.

• 

  Lexicon's AAK1 Inhibitor Disappoints in Phase II Postherpetic Neuralgia Study

  12/22/2022

  Lexicon Pharmaceuticals’ LX9211 fell short of its primary efficacy endpoint, according to topline data from the Phase II RELIEF-PHN-1 study in post-herpetic neuralgia.

• Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia

  12/21/2022

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced topline results of RELIEF-PHN-1, its Phase 2 proof-of-concept study of LX9211 in postherpetic neuralgia.

• Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference

  11/28/2022

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2022.

• Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit

  11/14/2022

  Lexicon Pharmaceuticals, Inc. announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit in Washington, D.C.

• Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference

  11/11/2022

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022.

• Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update

  11/9/2022

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2022 and provided an update on key corporate milestones.

• Lexicon Pharmaceuticals Highlights Oral Presentation of Final Results From the RELIEF-DPN-1 Trial of LX9211 at the 16th Annual Pain Therapeutics Summit

  11/8/2022

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its investigational drug LX9211, a novel, highly selective inhibitor of adaptor-associated kinase 1 (AAK1), will be presented during a podium presentation at the 16th Annual Pain Therapeutics Summit in Washington, D.C.

• New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

  11/6/2022

  Lexicon Pharmaceuticals, Inc., announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational heart failure treatment sotagliflozin, was presented at the American Heart Association Scientific Sessions 2022 in Chicago, Illinois.

• New Analysis of SCORED Trial Demonstrates Sotagliflozin’s Effect on Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

  11/5/2022

  Lexicon Pharmaceuticals, Inc. announced that a new post hoc analysis of results from the SCORED Phase 3 outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, was presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting in Orlando, Florida.

• Lexicon Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

  11/4/2022

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the markets close.

• New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022

  10/31/2022

  Lexicon Pharmaceuticals, Inc., announced the upcoming presentation of new analyses of results from the SOLOIST-WHF and SCORED Phase 3 outcomes studies of its investigational sotagliflozin product at the American Heart Association Scientific Sessions 2022 in Chicago, Illinois.

• Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

  10/24/2022

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany.

• 

  Clinical Catch-Up: Scandion Oncology, Edesa Biotech, Clovis & More 

  10/3/2022

  Scandion Oncology, Edesa, Clovis, Lexicon and Cytokinetics share a string of positive news from their clinical trials on heart failure, cancer, COVID-19 and ARDS. 

• New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events

  10/2/2022

  Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, was presented at the Heart Failure Society of America Annual Scientific Meeting 2022.

• Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy

  9/20/2022

  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of scientific and medical presentations describing the progression of its investigational drug LX9211 from discovery to translation in a clinical proof-of-concept study.